Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

To determine the response rate of pazopanib when administered as monotherapy in patients with unresectable neuroendocrine tumor.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neuroendocrine Tumor Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Neuroectodermal Tumors Neuroendocrine Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Samsung Cancer Center

Seoul, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

low to intermediate grade neuroendocrine tumor not amenable to surgery or local therapy

Exclusion criteria

poorly differentiated (high grade or anaplastic)/small cell, pheochromocytoma

Treatment and study plan

Pazopanib

Drug

Pazopanib 800 mg qd daily

Primary outcomes

response rate

Time frame: 1~2 year

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Registry information

Official study title

Phase II Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

Important dates

Study start: 2010
Primary completion: 2012
Study completion: 2013
First posted: Apr 7, 2010
Registry last updated: Dec 29, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed